Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.

ABSTRACT:

Context

Radioiodine ablation is commonly used to treat thyroid cancer, but a major challenge is often the loss of radioiodine avidity of the cancer caused by aberrant silencing of iodide-handling genes.

Objectives

This study was conducted to test the therapeutic potential of targeting the aberrantly activated MAPK and PI3K/Akt/mTOR pathways and histone deacetylase to restore radioiodine avidity in thyroid cancer cells.

Experimental design

We tested the effects of specific inhibitors targeting these pathways/molecules that had established clinical applicability, including the MAPK kinase inhibitor RDEA119, mTOR inhibitor temsirolimus, Akt inhibitor perifosine, and histone deacetylase inhibitor SAHA, individually or in combinations, on the expression of iodide-handling

SUBMITTER: Hou P 

PROVIDER: S-EPMC2840852 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature